Is the 6MWT still the best endpoint for Pompe disease clinical trials?

The 6-minute walk test has long been the consensus primary measure for Pompe disease drug studies, but some experts are calling for change.

Related Keywords

Italy ,Barry Byrne ,Sanofi Nexviazyme ,Carlos Javier Alm ,Corrado Angelini ,Gerald Cox ,Genzyme Myozyme ,Powell Gene Therapy Center ,Contract Manufacturing Organisation ,Contract Research Organisation For Clinical Trials ,University Of Florida ,Neuromuscular Center ,University Of Padua ,Forced Vital Capacity ,Astellas Gene Therapies ,Spark Therapeutics ,Clinical Trials Arena ,Manufacturing Organisation ,Pharmaceutical Supply ,Event Conception ,Research Organisation ,